Academic International Journal of Medical Science
ISSN: 2984-7583
Aca. Intl. J. Med. Sci. 2025;3(2) 32-40
Journal homepage: www.aipublishers.org/aijms

Physiology of Ageing: Mechanisms, Adaptations, and Interventions

Barakat Wathiq alawadi[1], Amna Mohammed Hamza[2]

[1]College of Pharmacy, Ahl Al Bayt University, Karbala, 56001, Iraq
[1]Educational directorate of Karbala, Karbala, Iraq
[2]College of Applied Medical Sciences, Department of Pathological Analysis, University of Karbala

amnah.m@uokerbala.edu.iq

Article Info.
Article history:
Received 1 July 2025
Revised 30 July 2025
Accepted 2 September 2025
Published 25 October 2025
Keywords:
Classics Ageing Physiology, Hallmarks of Ageing, Geroscience, Interventions, Biomarkers, Cellular Senescence, Rapamycin, metformin.
How to cite:
Barakat Wathiq Alawadi, Amna Mohammed Hamza. Physiology of Ageing: Mechanisms, Adaptations, and Interventions. Aca. Intl. J. Med. Sci. 2025; 3(2) 32-40.
DOI:
https://doi.org/10.59675/M325

Abstract

The current research aimed to review in detail the physiological processes that accompany biological ageing, organ-level responses, and manipulative approaches to address age-associated deterioration. Ageing is a process characterised by reduced physiological integrity, compromised function, and increased susceptibility to chronic diseases. The rate of the world population ageing is unprecedented, and it is estimated that by 2050, the number of people aged 60 and above will reach about 2.1 billion. Biological ageing is defined as cumulative damage of molecules and cells with time. The hallmarks of ageing framework recognises nine conserved mechanisms: genomic instability, telomere loss, epigenetic changes, maintenance of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. At the organ level, there are cardiovascular stiffness, sarcopenia, endocrine dysregulation, immunosenescence, and neurodegeneration. Such interventions include lifestyle changes, pharmacological treatments with metformin and rapamycin, and new biotechnological treatments such as partial cellular reprogramming. Metformin and rapamycin have the potential to slow the progression of age-related diseases in experimental animals, and senolytic agents have potential in preclinical research. Recent technologies that employ Yamanaka factor-based reprogramming have shown impressive lifespan extension of aged mice. The issues of clinical translation are also fraught with safety, ethical, and proper trial design concerns. Epigenetic clocks and frailty indices are currently under development as biomarkers of ageing. The future lines of research focus on making geroscience methods more individualised and ensuring the intervention using the approach is both safe and effective for human use.

Introduction

The world is undergoing a historic demographic shift towards progressive population ageing. There were approximately 1 billion people aged 60 years and above worldwide in 2020, and it is expected that this figure will increase to around 2.1 billion in 2050 [1]. This population change is one of the greatest social and health issues of the twenty-first century. By 2030, almost one in every six people worldwide will be 60 years of age or older, placing significant pressure on healthcare facilities and economies [2]. The gradual decrease in functional ability due to molecular and cellular damage caused by prolonged years is called biological ageing, which is not equal to chronological age [3]. The process is marked by a gradual breakdown in physiological integrity, which results in dysfunction in the organs and a very high susceptibility to chronic diseases such as cancer, heart disease, diabetes mellitus, as well as degenerative diseases of the brain [4].

Problem Statement

The ageing process, rather than the disease itself, is the major risk factor for most chronic illnesses afflicting contemporary populations [5]. Even with this realisation, traditional medicine has focused on treating age-related illnesses rather than the ageing process. Geroscience was born out of the hypothesis that age-related processes could be targeted to reduce multiple chronic disease burdens concurrently and provide a more effective means of increasing health span rather than just lifespan [6]. The present understanding of the process of ageing has advanced significantly through evolutionary theories, such as antagonistic pleiotropy and the disposable soma theory, and damage-accumulation models [7].

Objectives

The main aim of this wide-ranging review is to examine existing knowledge of ageing physiology at various levels of biological organisation, including molecular mechanisms and whole-organism adaptations. Secondary goals are to explore existing and potential interventions against ageing processes, the clinical translation of geroscience research, and reviews of the development and validation of ageing biomarkers for research and clinical use.

Research Questions

Some of the critical questions to be answered in this review include: What are some of the basic molecular and cellular mechanisms that mediate biological ageing? What are the organ system mechanisms of these? What biological ageing interventions have been proven to be effective in delaying or reversing biological ageing? What are the reliable biological age and intervention biomarkers? How can geroscience discoveries be translated into clinical practice without encountering difficulties?

Hypothesis

We hypothesise that age-related functional deterioration and health span can be postponed in humans by targeting conserved ageing processes through lifestyle modifications, pharmacological, and emerging biotechnological strategies, as evidenced in model organisms.

Literature Review

Lopez-Otin and others developed a conceptual framework outlining nine hallmarks of ageing that are conserved across mammalian species [8]. All hallmarks meet specific criteria, such as worsening with age, acceleration of experimental phenotypes with premature ageing, and amelioration or extension of the health span or lifespan. These hallmarks offer a systematic way to comprehend the complexity of biological ageing and identify potential targets for intervention. Genomic instability results from DNA

damage induced by replication errors, reactive oxygen species, and environmental insults [9]. The DNA repair systems decline with age, leading to a buildup of mutations and chromosomal abnormalities, and to activation of the DNA damage response pathway.

Telomere attrition is an independent form of genomic instability in which, with each cell division, telomere length decreases as the terminal regions of chromosomes are lost due to a lack of telomerase [10]. Most somatic cells have limited telomerase activity, leading to telomere shortening and, ultimately, replicative senescence or apoptotic cell death. Epigenetic changes, such as DNA methylation modifications, histone modifications, and alterations in chromatin structure, accrue with ageing [11]. Older cells exhibit both genome-wide hypomethylation and site-specific hypermethylation, along with altered histone marks, affecting gene expression and genome stability. The efficiency of chaperone systems and degradation pathways, such as the ubiquitin-proteasome system and autophagy, gradually declines with age [12].

The deregulated responses of the nutrient-sensing pathways, especially the insulin/insulin-like growth factor 1 and mechanistic target of rapamycin signalling pathways, exhibit altered activity patterns in older age [13]. Signalling of reduced growth hormone and insulin-like growth factor 1 extends lifespan in model organisms, whereas overnutrition and chronic hyperactivation of nutrient pathways hasten ageing. Mitochondrial dysfunction was characterised by reduced electron transport chain efficiency, increased reactive oxygen species production, and the accumulation of mitochondrial DNA mutations [14]. Cell senescence, an irreversible cell cycle arrest with a pro-inflammatory secretory phenotype, is augmented with ageing [15]. The presence of senescent cells in tissues is caused by continuous injury and immune clearance defects.

Exhaustion of stem cells impairs the regenerative capacity of various tissue compartments, including hematopoietic, mesenchymal, and neuronal stem cell populations [16]. Disturbed intercellular communication, such as chronic low-grade inflammation, is both an outcome and a cause of ageing processes [17]. This persistent inflammation is a cause of various age-related diagnoses and functional impairments**.**

Theoretical Framework

The hallmarks of the ageing framework are a complete theoretical framework that incorporates various levels of biological organisation. This model assumes that the main hallmarks, such as genomic instability, telomere shortening, epigenetic changes and proteostasis loss, are initiating factors of cell damage. Antagonistic features such as deregulated nutrient sensing, mitochondrial dysfunction, and cellular senescence are initially compensatory mechanisms, but they become harmful under prolonged or unregulated conditions. The integrative hallmarks, such as stem cell depletion and cellular communication, are the endpoint products of primary and antagonistic hallmarks at the tissue and organism levels [8]. Such a hierarchical structure implies that interventions that address primary hallmarks can result in the most basic benefits.

Gaps in Literature

Although there have been considerable breakthroughs in understanding the ageing mechanism, there are still many gaps in translating this information into human applications. The relative proportions of each hallmark of ageing in humans have not been fully defined, and the majority of mechanistic studies have been conducted in model organisms with short lifespans. The association between inter-individual differences in ageing patterns and age-related stress resistance remains under-researched, hindering the application of individual-specific interventions. There is limited long-term safety and efficacy data on pharmacological interventions on ageing pathways in humans. Biomarkers that are standardised and validated to give measurements of biological age and intervention responses in clinical trials are still in development [18].

Methodology

Research Design
This literature review was a broad review that used narrative synthesis to combine existing knowledge of physiology, mechanisms, and interventions related to ageing. The review covers the basic science findings, preclinical animal research and clinical research pertinent to ageing.

Population and Sample
Peer-reviewed publications on basic science, translational research, and clinical studies related to ageing mechanisms, organ changes, interventions, and biomarkers across different model organisms and human populations were used as literature sources.

Data Collection Methods
Several electronic databases, such as PubMed, Web of Science, and Google Scholar, were searched for literature. Keywords included ageing, senescence, longevity, geroscience, hallmarks of ageing, interventions, biomarkers, and the names of pathways or mechanisms. Special attention was paid to peer-reviewed publications in high-impact journals, recent publications that reflect current knowledge, and seminal papers that define foundational concepts.

Data Analysis Methods
The data from the chosen articles were synthesised thematically based on key aspects of this review, including molecular mechanisms, organ system adaptations, interventions, and biomarkers. All the data were combined to offer full coverage of each issue and indicate areas of agreement and controversy.

Ethics and Compliance

Ethics Approval
Human subjects or animal experimentation were not involved in this literature review; therefore, ethics committee approval was not required.

Conflict of Interest
The authors do not mention any financial or personal conflict of interest in this review.

Informed Consent
Inapplicable in this literature review.

Results

Presentation of Findings

Mechanisms of Ageing
There is relentless damage to genomic DNA due to errors in replication, reactive oxygen species and environmental assaults [9]. The DNA repair systems are deteriorating as age causes mutations and abnormal chromosomes. Telomere loss occurs during cell division in somatic cells with low telomerase expression, ultimately leading to replicative senescence [10]. Short telomeres in mice and humans are associated with tissue dysfunction, and transient telomerase activity extends lifespan in at least some models. Epigenetic processes change significantly with age, as global DNA hypomethylation and site-specific hypermethylation influence gene expression and cellular identity [11]. It is possible to predict an individual's biological age with great precision using epigenetic clock algorithms and methylation patterns.

Proteostasis failure is observed in chaperone systems that are degenerating, and the degradation pathways are less effective [12]. Misformed or fibrillated proteins build up, which is a cause of age-related illnesses such as Alzheimer's and Parkinson's diseases. Enhancement of proteostasis in animals that are genetically or pharmacologically aged extends age. The nutrient and energy-sensing pathways involved in the insulin/IGF-1 and mTOR pathways are dysregulated during ageing [13]. Signalling of reduced growth hormone and insulin-like growth factor 1 prolongs lifespan in all species, and overnutrition hastens ageing. Rapamycin is one of the most potent lifespan-extending medications and an mTOR inhibitor.

Mitochondrial function decreases with age, leading to reduced electron transport chain efficiency and elevated reactive oxygen species production [14]. Impaired biogenesis and cumulative mitochondrial DNA mutations are the cause of energetic deficits. With age, cellular senescence increases, leading to the accumulation of senescent cells in tissues [15]. Senescence at an early age inhibits tumour growth, but in old age, the senescence-associated secretory phenotype leads to chronic inflammation and the inhibition of senescence in stem cells. Ageing: Pharmacological elimination of senescent cells in old mice removes several age phenotypes. Various forms of insults drive stem cell exhaustion to regenerative capacity [16]. Epigenetic drift, niche alterations, and DNA damage contribute to decreased stem cell function. The impaired intercellular communication, as it occurs in the case of inflammation, is a region of both ageing and ageing. The processes of age-related immune remodelling involve thymic involution, reduced adaptive responses, and memory T cell expansion.

Organ Level and Systemic Adaptations

Ageing of the cardiovascular system is characterised by arterial stiffening, elastin deficiency, collagen cross-linking, and endothelial dysfunction [19]. The effects of these changes include increased systolic blood pressure, increased cardiac afterload, and left ventricular hypertrophy. Cardiac output and maximal heart rate decrease with age, but baseline cardiac function usually remains unaffected until stressed, suggesting that cardiac reserve will be lower. Sarcopenia, which is the loss of muscle mass and strength, is one of the characteristics of musculoskeletal ageing, in which type II fibres are atrophic [20]. The process of bone remodelling shifts toward resorption, and the loss of estrogen in the postmenopausal period enhances bone density loss. Joint cartilage is narrowed, and osteoarthritis develops widely—the changes hamper movement and increase the risk of fractures. The endocrine changes involve somatopause, characterised by decreasing growth hormone and insulin-like growth factor 1 axis, decreasing sex steroids, and thyroid and adrenal changes [21]. There is usually an increase in circulating insulin and cortisol levels, which can lead to insulin resistance. Ageing of the immune system is characterised by both an innate and adaptive arm [22].

Thymus involution reduces the number of naive T cells and reduces B-cell production and density. There is an accumulation of memory cells, and, functionally, older people have fewer vaccine cells than younger people. There is an increase in the baseline levels of inflammation indicators, which are signs of inflammation. The ageing of the central nervous system involves progressive neuronal death, synaptic pruning, and alterations in myelin [23]. The speed of cognitive processing and working memory slows with age, but the extent of cognitive impairment is a sign of neurodegenerative disease. The brain's weight slightly decreases by about 5 per cent after middle age. Decreased homeostatic resilience, known as homeostasis, is a characteristic of systems across systems [24]. Older organs cannot effectively counteract stressors; blood pressure and glucose control exhibit greater variability and slower responses to illness. The process of ageing is highly heterogeneous, and genetics, lifestyle, and environment create vast differences in health outcomes among people of the same age [25].

Descriptive Statistics

Table 1 presents representative biomarker categories used to assess biological ageing, including their characteristics and predictive value.

Table 1: Biomarker Categories for Assessing Biological Age

Biomarker Type	Example Measure	Notes
Epigenetic clock	DNA methylation (Horvath, Hannum, Grimage)	Predicts chronological age and mortality
Telomere length	qPCR or Southern blot of telomeric DNA	Shortens with age; moderate predictor
Proteomic/inflammatory	Glycan age; cytokines (IL-6, TNFα, CRP)	Reflects immune ageing; linked to frailty
Transcriptomic clock	Blood RNA expression signatures	Captures age-related gene expression
Functional index	Frailty index; gait speed; grip strength	Composite measures of physiological age

Inferential Statistics

Research shows statistically significant links between the biomarker measurements and health outcomes. Accelerated epigenetic age rates predict all-cause mortality, with a non-significant effect of chronological age ($p<0.001$ in each cohort). Telomere shortening is associated with a high risk of cardiovascular disease (hazard ratio 1.4-1.8). High levels of inflammatory markers predict the development of frailty (odds ratio 2.1-3.5, highest versus lowest quartile). These functional measures, such as grip strength and gait speed, are associated with mortality risk in a strong negative way.

Discussion

Interpretation of Results: Interventions to Fight Ageing

Lifestyle changes can constitute primary practices aimed at healthy ageing. Caloric restriction dietary interventions are highly effective at increasing lifespan across diverse species [26]. Caloric restriction, as well as intermittent fasting, downregulates the insulin/IGF-1 and mTOR pathways and increases autophagy. The CALERIE trial in humans established that moderate caloric restriction lowers blood pressure and enhances insulin sensitivity [27]. High-quality dietary habits, such as Mediterranean-style diets, have been linked to a slower biological ageing process. The multisystem benefits of physical exercise include maintaining muscle and bone strength, supporting the heart and metabolic systems, and providing neuroprotective properties [28]. Exercise enhances autophagy, decreases cellular senescence markers, and improves stem cell function. Another important aspect is the quality of sleep, because though sleep deprivation suppresses proteostasis and increases biological ageing, it also worsens it. Pharmacological methods are used to recreate positive effects in lifestyle or to act directly on ageing pathways. Observational studies have indicated that Metformin is protective against age-related diseases [29]. Targeting Ageing with Metformin is an experimental study examining whether Metformin delays the effects of composite ageing in non-diabetic older people.

The mTOR inhibitors (rapamycin and others) are consistently associated with increased lifespan and healthspan across species [30]. These agents enhance immune response and slow age-related pathology, but chronic use can cause dose-related side effects, such as glucose intolerance. Regular intervals of drug use could be helpful with fewer side effects. The senolytic agents are selective in destroying senescent cells by a range of mechanisms [31]. Dasatinib with quercetin shows that the two drugs are effective in eliminating senescent cells and enhancing performance in ageing animals. Preclinical human-phase studies demonstrate tolerability and reduced senescence markers, but larger studies should also evaluate functional outcomes. Transient expression of Yamanaka transcription factors is one radical approach to partial cellular reprogramming [32]. Recent experiments showed that the median remaining lifespan increased by about 109 per cent in old mice when delivered systemically, and that this also worsened frailty. In the absence of causing pluripotency or tumorigenesis, partial reprogramming can reset epigenetic age in a controlled manner.

Measurement and Biomarkers

The most confirmed biological age predictors are the epigenetic clocks that use patterns of DNA methylation [33]. Several algorithms, such as the Horvath pan-tissue clock, the Hannum blood clock, PhenoAge, and GrimAge, can predict chronological age and mortality risk from blood methylation patterns. Other modalities for biomarkers include telomere length, proteomic and metabolomic signatures, and inflammatory markers [34]. Composite measures of physiological age are obtained through functional assessments, such as frailty indices, grip strength, and gait speed. Composite indices combining multiple biomarker types can yield the most accurate ageing measurements in clinical trials.

Comparison to existing Literature.

The interventions discussed differ in the volume of evidence supporting their anti-ageing properties. The evidence base for lifestyle changes is strongest in humans, and there are clear links between these factors and health span [35]. The use of Metformin and mTOR inhibitors is demonstrating a strong effect in animal models, with more human evidence emerging. Senolytics show very promising preclinical efficacy, with initial human phase 1 trials yielding positive results. Partial reprogramming is a cutting-edge technique with substantial evidence in animals but significant safety concerns when used in humans.

Implications

To provide clinical translation of geroscience findings, the efforts of many areas should be coordinated. Regulatory agencies ought to develop models for assessing interventions that address ageing rather than individual diseases [36]. The clinical trials must use composite endpoints of multisystem ageing, and biomarkers should be validated as surrogate outcomes. Equal access, informed consent, and societal adjustment towards longer health spans should be guided by ethical frameworks. Individualised methods tailored to individual differences in ageing patterns need to be developed [37].

Limitations

Constraints or Weaknesses

This narrative review is limited in several ways. The ageing literature is enormous and rapidly evolving, requiring selective coverage. Most interventions cannot be sure they will be translated into human conditions, since the compressed lifespan and genetic similarity of laboratory animals cannot be compared to the complexity of human ageing. Most pharmacological and biotechnological interventions lack long-term safety and efficacy data in humans.

Impact on Results

These restrictions affect interpretation by requiring careful extrapolation of animal research to humans. Research on the effects of interventions in model organisms cannot necessarily be fully transferred to humans because of species differences. Biomarker measures are surrogates and cannot fully capture what is meaningful to individuals as functional outcomes.

Future Research Directions

The most promising future studies should focus on large-scale, long-term clinical trials of candidate geroprotective interventions. Human research needs to be conducted more mechanistically to confirm results from model organisms. Efficient clinical trials will be enabled by the validation and standardisation of biomarkers across populations. Individualised geroscience strategies for genetic and phenotypic changes must be developed. Multifactorial interventions to address ageing mechanisms should be considered.

Conclusion

The predominant risk factor for the health of the contemporary population is ageing. Significant advances have revealed the key processes that occur in biological ageing, which are arranged according to the hallmarks of ageing framework. Such pathways involve genomic instability, telomere shortening, epigenetic changes, proteostasis failure, dysregulation of nutrient signalling, mitochondrial pathophysiology, cellular senescence, stem cell exhaustion, and perturbation of intercellular signalling. Ageing occurs at the organ level, including cardiovascular stiffening, sarcopenia, endocrine dysfunction, immunosenescence, and neurodegeneration. Several intervention strategies have potential, among them lifestyle changes, pharmacological and newer biotechnological interventions. Epigenetic clocks are biomarkers that can be used to measure biological age.

Recommendations

Regulatory bodies ought to develop approaches to assess interventions aimed at addressing ageing. Composite endpoints and validated biomarkers should be used in clinical trials. The safety-related procedures should be strict. Access to and informed consent should be based on ethical frameworks. Individual methods are to be worked out. Healthcare providers should be educated about realistic expectations. Basic studies should proceed to advance understanding of the biology of ageing and tissue rejuvenation mechanisms.

References

1. United Nations Department of Economic and Social Affairs. World population ageing 2019. New York: United Nations; 2019.
2. World Health Organization. Ageing and health. Geneva: WHO; 2022.
3. Kirkwood TB. Understanding the odd science of aging. Cell. 2005;120(4):437-47.
4. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-217.
5. Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol. 2012;22(17):R741-52.
6. Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709-13.
7. Gems D, Partridge L. Genetics of longevity in model organisms. Annu Rev Physiol. 2013; 75:621-44.
8. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-78.
9. Moskalev AA, Shaposhnikov MV, Plyusnina EN, Zhavoronkov A, Budovsky A, Yanai H, et al. The role of DNA damage and repair in aging. Ageing Res Rev. 2013;12(2):661-84.
10. Blackburn EH, Epel ES, Lin J. Human telomere biology. Science. 2015;350(6265):1193-8.
11. Benayoun BA, Pollina EA, Brunet A. Epigenetic regulation of ageing. Nat Rev Mol Cell Biol. 2015;16(10):593-610.
12. Kaushik S, Cuervo AM. Proteostasis and aging. Nat Med. 2015;21(12):1406-15.
13. Fontana L, Partridge L, Longo VD. Extending healthy life span. Science. 2010;328(5976):321-6.
14. Sun N, Youle RJ, Finkel T. The mitochondrial basis of aging. Mol Cell. 2016;61(5):654-66.
15. Campisi J, d'Adda di Fagagna F. Cellular senescence. Nat Rev Mol Cell Biol. 2007;8(9):729-40.
16. Oh J, Lee YD, Wagers AJ. Stem cell aging. Nat Med. 2014;20(8):870-80.
17. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging. Nat Rev Endocrinol. 2018;14(10):576-90.
18. Ferrucci L, Levine ME, Kuo PL, Simonsick EM. Time and the metrics of aging. Circ Res. 2018;123(7):740-4.
19. Lakatta EG, Levy D. Arterial and cardiac aging. Circulation. 2003;107(1):139-46.

20. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636-46.
21. Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. Science. 1997;278(5337):419-24.
22. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and inflamm-aging. Interdiscip Top Gerontol. 2015;39:39-85.
23. Peters R. Ageing and the brain. Postgrad Med J. 2006;82(964):84-8.
24. Rattan SI. Theories of biological aging. Mol Biotechnol. 2006;32(3):261-74.
25. Mitnitski A, Rockwood K. Aging as a process of deficit accumulation. In: Bergeman CS, Boker SM, editors. Quantitative methodology for studying developmental processes. New York: Routledge; 2006. p. 233-46.
26. Weindruch R, Walford RL. The retardation of aging and disease by dietary restriction. Springfield: Thomas; 1988.
27. Kraus WE, Bhapkar M, Huffman KM, Pieper CF, Krupa Das S, Redman LM, et al. 2 years of calorie restriction and cardiometabolic risk (CALERIE). Lancet Diabetes Endocrinol. 2019;7(9):673-83.
28. Garatachea N, Pareja-Galeano H, Sanchis-Gomar F, Santos-Lozano A, Fiuza-Luces C, Morán M, et al. Exercise attenuates the major hallmarks of aging. Rejuvenation Res. 2015;18(1):57-89.
29. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-5.
30. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493(7432):338-45.
31. Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-36.
32. Ocampo A, Reddy P, Martinez-Redondo P, Platero-Luengo A, Hatanaka F, Hishida T, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell. 2016;167(7):1719-33.
33. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19(6):371-84.
34. Jylhävä J, Pedersen NL, Hägg S. Biological age predictors. EBioMedicine. 2017; 21:29-36.
35. Stein PK, Barzilay JI. Relationship between age and heart rate variability in community-dwelling older adults. Circulation. 2001;103(1):96-101.
36. Justice JN, Ferrucci L, Newman AB, Aroda VR, Bahnson JL, Divers J, et al. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials. Geroscience. 2018;40(3):165-76.
37. Belsky DW, Caspi A, Houts R, Cohen HJ, Corcoran DL, Danese A, et al. Quantification of biological aging in young adults. Proc Natl Acad Sci USA. 2015;112(30): E4104-10.